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https://doi.org/10.1016/j.healun.2021.07.BACKGROUND: Use of cardiac grafts obtained with donation after circulatory death (DCD) could signif-
icantly improve donor heart availability. As DCD hearts undergo potentially deleterious warm ische-
mia and reperfusion, clinical protocols require optimization to ensure graft quality. Thus, we
investigated effects of alternative preservation conditions on endothelial and/or vascular and contractile
function in comparison with the current clinical standard.
METHODS: Using a rat DCD model, we compared currently used graft preservation conditions, St.
Thomas n˚2 (St. T) at 4˚C, with potentially more suitable conditions for DCD hearts, adenosine-lido-
caine preservation solution (A-L) at 4˚C or 22˚C. Following general anesthesia and diaphragm transec-
tion, hearts underwent either 0 or 18 min of in-situ warm ischemia, were explanted, flushed and stored
for 15 min with either St. T at 4˚C or A-L at 4˚C or 22˚C, and then reperfused under normothermic, aer-
obic conditions. Endothelial integrity and contractile function were determined.
RESULTS: Compared to 4˚C preservation, 22˚C A-L significantly increased endothelial nitric oxide syn-
thase (eNOS) dimerization and reduced oxidative tissue damage (p < 0.05 for all). Furthermore, A-L at
22˚C better preserved the endothelial glycocalyx and coronary flow compared with St. T, tended to
reduce tissue calcium overload, and stimulated pro-survival signaling. No significant differences were
observed in cardiac function among ischemic groups.
CONCLUSIONS: Twenty-two-degree Celsius A-L solution better preserves the coronary endothelium
compared to 4˚C St. T, which likely results from greater eNOS dimerization, reduced oxidative stress,
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2 The Journal of Heart and Lung Transplantation, Vol 00, No 00, Month 2021conditions immediately following warm ischemia constitutes a promising approach for the optimiza-
tion of clinical protocols in DCD heart transplantation.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/)Heart transplantation with donation after circulatory death
(DCD) may provide a solution to limitations in heart trans-
plantation that result from lack of donor organs. Although
heart transplantation remains the gold standard treatment for
patients with end-stage heart failure,1 the number of patients
on heart transplantation waiting lists has increased over the
last 2 decades, while the number of potential donors has
remained stable, leading to a major organ shortage.2,3 As an
additional method to conventional donation after brain death
(DBD), DCD could substantially improve the number of car-
diac grafts available for transplantation2 and potentially reduce
mortality rates for patients on the heart waiting list by 40%.4
Indeed, increases in cardiac transplant activity of 48% have
been reported in the UK5 and up to 15% in Australia6 as a
result of the implementation of DCD heart transplantation pro-
grams. Although DCD hearts undergo an inevitable period of
warm ischemia followed by reperfusion (I/R), which raises
concern for graft quality, more than 120 DCD hearts have
been transplanted since 2014,5,6 providing comparable short-
and mid- term outcomes to DBD.5,6
In the context of DCD, it is critical to apply cardioprotec-
tive therapies at the onset of reperfusion as interventions to
treat potential grafts in the donor are limited for ethical rea-
sons. The majority of human DCD hearts are procured directly
and flushed immediately after warm ischemia with the hyper-
kalemic preservation solution, St. Thomas n˚2 cardioplegia
(St. T), supplemented with erythropoietin (EPO) and glyceryl-
trinitrate (GTN) for 3 to 6 min.6-8 Erythropoietin is known to
activate the reperfusion injury salvage kinase (RISK) and sur-
vivor activating factor enhancement (SAFE) pathways, while
glyceryl-trinitrate acts as a donor of nitric oxide, in addition to
stimulating pro-survival kinases.9 Hearts are then stored in
hypothermic, non−perfused conditions from 15 to 30 min
while preparations are made for perfusion in the Organ Care
System (OCSTM Heart, Transmedics, Massachusetts, US).6,8-
12 Concerns about the use of hyperkalemic cardioplegic solu-
tions and profound hypothermia have been raised, given that
these conditions may exacerbate I/R injury in the context of
DCD.9,11,13,14 More specifically, it has been demonstrated that
profound hypothermia and hyperkalemic cardioplegia are det-
rimental for the vascular endothelium.13,14 Potential alterna-
tives to the current preservation solutions, such as
normokalemic adenosine-lidocaine cardioplegia (A-L), have
been proposed.11,13 Given that endothelial dysfunction is a
key mediator of transplantation injury as it may result in the
no-reflow phenomenon15,16 or potentially lead to cardiac allo-
graft vasculopathy,17 there is an urgent need to optimize the
initial reperfusion conditions to preserve the endothelium.18
As few studies have investigated the specific effects of preser-
vation solutions, such as adenosine-lidocaine and underconditions that do not fully represent the clinical DCD setting,
further research is required to better characterize the effects
and mechanisms of varying preservation conditions in the con-
text of DCD.11,13 Therefore, with the current study, we investi-
gated the effects of graft preservation conditions, using A-L at
tepid or cold temperatures, on endothelial and/or vascular and
contractile function and the corresponding mechanisms in
comparison with the current clinical standard (cold St. T) to
help optimize clinical DCD heart transplantation protocols.Methods
Ethics statement
All experiments were performed according to the European Con-
vention for Animal Care and were approved by the Swiss animal
welfare authorities and state veterinary office (Ethics Committee
for Animal Experimentation [ECAE], Berne, Switzerland).Experimental protocol
Simulation of withdrawal of life sustaining therapy
and ischemia in situ
55 adult male Wistar rats (Janvier Labs, Le Genest-Saint-Isle,
France), housed under standard conditions with unlimited access to
food and water, were anesthetized intraperitoneally with 78 mg/kg
ketamine (Narketan; Vetoquinol AG, Berne, Switzerland), 7.2 mg/kg
xylazine (Xylapan; Vetoquinol AG, Berne, Switzerland) and
1.2 mg/kg acepromazine (Prequillan, Fatro AG, Bologna, Italy). Sim-
ulation of withdrawal of life sustaining therapy and in-situ ischemia
were performed as described.19,20 Briefly, withdrawal of life sustain-
ing therapy (WLST) was simulated by asphyxiation following tran-
section of the diaphragm. Functional warm ischemic time (FWIT)
was considered to start when the peak systolic pressure dropped
below 50 mm Hg and lasted either for 0 min (hearts were immedi-
ately explanted) or 18 min. Body temperature was maintained
between 36.6 and 37.2˚C during ischemia.
Preservation and storage conditions
After explantation, hearts were cannulated via the aorta on an ex-
situ perfusion system. Four experimental groups were compared
(Figure 1): A no-warm ischemia control (NWI) group (A) and an
18 min ischemia group (B) were flushed with cold (4˚C) St. T
preservation solution supplemented with 100 mg/L glyceryl trini-
trate (GTN: Nitroglycerin Bioren; Sintetica, Mendrisio, Switzer-
land) and 5000 units/L erythropoietin (EPO: Eprex; Janssen,
Berchem, Belgium).21 In the third and fourth experimental groups,
hearts underwent 18 min of ischemia and were then flushed with
adenosine-lidocaine (A-L) solution at either 4˚C (C) or at 22˚C
(D). All hearts were flushed for 3 min at a constant pressure of
Figure 1 Experimental protocol: In a first perfusion series, hearts were subjected to either 0 (A) or 18 min (B-D) of in situ ischemia then
hearts were explanted and subjected to differing cardioplegic flush and static storage conditions (Groups A and B: 4˚C St. Thomas n˚2 solu-
tion supplemented with glyceryl trinitrate and erythropoietin; Group C: 4˚C normokalemic adenosine-lidocaine cardioplegia or Group D:
22˚C normokalemic adenosine-lidocaine preservation solution). Afterward, all hearts were reperfused for 60 min and contractile recovery,
circulating markers of cell death, signaling molecules, edema, eNOS coupling, inflammation markers, glycocalyx components, and oxida-
tive stress were assessed. In a second perfusion series, endothelial function was assessed after 30 min reperfusion. A-L, normokalemic aden-
osine-lidocaine cardioplegia; CP, cardioplegic flush; Psyst, peak systolic pressure; St. T, St. Thomas n˚2 cardioplegia; WLST, simulated
withdrawal of life sustaining therapy.
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sion using the corresponding preservation conditions (flush solu-
tion and temperature).
Normothermic reperfusion
Two series of heart perfusions were generated after the static stor-
age: one series was reperfused for 60 min to monitor post-ische-
mic contractile recovery and perform biochemical assays (cardiac
recovery series, n = 6-8 rats per group), and the second series was
reperfused for 30 min to assess endothelial function (endothelial
recovery series, n = 5-8 rats per group). Both series were reper-
fused with modified Krebs-Henseleit buffer containing 1.25 mM
Ca2+ and 11 mM glucose. For the first 10 min of reperfusion,
hearts were perfused in the unloaded mode with a constant pres-
sure of 60 mm Hg, and then switched to working mode with the
minimum perfusion pressure set to 60 mm Hg. Throughout the
reperfusion period, heart temperature was maintained at 37˚C and
buffers gassed with 95% O2 and 5% CO2. At the end of the reper-
fusion period, ventricular tissue was quickly frozen in liquid nitro-
gen, and stored at -80˚C.Data analysis
All results are reported as mean § standard deviation. Statistical
analyses were performed with GraphPad Prism software (Graph-
Pad Software, Inc., La Jolla, CA). Outlier values were identified
with the Tukey test when data were outside the inner fences of the
box and whiskers plot and removed from the analysis.22 The Krus-
kal-Wallis test was performed for an overview of differencesbetween experimental groups and, when significant, pairwise com-
parisons between groups were performed with Mann-Whitney
tests. Correlations were analyzed using Spearman’s rank correla-
tion test. Two-tailed p-values were adjusted for multiple compari-
sons (modified, sequential, rejective Bonferroni procedure).23
Corrected p-values are reported and considered statistically signif-
icant if <0.05.Supplemental methods
The following methods are described in detail in the Supplemen-
tary material section online: endothelial and cardiac function eval-
uation, western blot, eNOS dimer determination, protein
carbonylation, syndecan-1 tissue content, calcium content, tissue
water content, cell death markers and mitochondrial damage, cyto-
kine measurements, cardiac oxygen consumption and efficiency,
mRNA expression, preservation solution components (Table S1)
and primer sequences used in analyses of mRNA expression
(Table S2).Results
Endothelial-related parameters
Coronary vascular resistance (CVR) during the initial flush,
coronary flow during reperfusion, and tissue glycocalyx
content are shown in Figure 2. CVR during the initial flush
was significantly increased in ischemic groups with St. T
and A-L at 4˚C compared with the NWI group and with the
Figure 2 Endothelial-related parameters. (A) Coronary vascular resistance during the cardioplegic flush; (B) Post-ischemic coronary
flow; (C) Tissue levels of glycocalyx component, syndecan 1(CD 138). *p < 0.05 vs St. T 4˚C (NWI), ˚p < 0.05. Data are expressed as
mean § SD; n = 4 to 7 per group. A-L, normokalemic adenosine-lidocaine solution; NWI, no warm ischemia; St. T, St. Thomas n˚2 solu-
tion.
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flow was significantly decreased in the ischemic group with
St. T at 4˚C compared to the NWI group during loaded
reperfusion (p < 0.05). Syndecan-1 (CD-138), a component
of the glycocalyx, was measured in tissue after 60 min
reperfusion. Syndecan-1 levels in ischemic hearts preserved
with St. T at 4˚C were significantly lower compared to the
NWI group, while hearts preserved with A-L maintained
similar levels as the NWI group (p < 0.05).eNOS dimerization and markers of oxidative
damage
To evaluate endothelial nitric oxide synthase (eNOS) cou-
pling, we measured the relative quantity of eNOS dimers
after 60 min reperfusion, as shown in Figure 3A and B. We
observed significantly more eNOS dimers in hearts with A-
L at 22˚C compared with the other 2 ischemic groups (p <
0.05 for both). Total tissue oxidative stress, represented by
protein carbonylation measured after 60 min reperfusion in
Figure 3C, was significantly lower in the group with A-L at
22˚C compared with the other 2 ischemic groups preservedat 4˚C, (p < 0.05 for both), with levels similar to the NWI
group. In addition, a representative protein carbonylation
blot is shown in S6.Calcium content
Calcium content, represented in Figure 4, was significantly
increased in all ischemic hearts at 60 min reperfusion com-
pared with the NWI group. Although among ischemic
groups, no significant differences were observed; there was
a tendency for higher calcium content in St. T at 4˚C com-
pared to tepid A-L. Furthermore, tissue calcium content
correlated negatively with post-ischemic cardiac function
(left ventricular work) and with endothelial integrity (glyco-
calyx content), and positively with a marker of mitochon-
drial damage (Cyt c release; p < 0.05 for all).Activation of key signaling molecules
Western blot analyses of phosphorylated (p) and total pro-
tein kinase B (Akt) and eNOS, analyzed after 60 min of
reperfusion, are presented in Figure 5. No significant
Figure 3 eNOS dimerization and oxidative stress. (A) Representative eNOS dimer western blots; (B) eNOS dimer content; (C) Protein
carbonylation indicating oxidative protein damage. *p < 0.05 vs St. T 4˚C (NWI), ˚p < 0.05. Data are expressed as mean § SD; n = 6 to 7
per group. A-L, normokalemic adenosine-lidocaine solution; DPC, denatured protein control; GAPDH, glyceraldehyde 3-phosphate dehy-
drogenase; kDa, kilodalton; NWI, no warm ischemia; Prot, protein; St. T, St. Thomas n˚2 solution.
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was significantly higher in all ischemic hearts compared to
the NWI group and in ischemic hearts with 22˚C A-L com-
pared with St. T (p < 0.05 for all).Post-ischemic functional recovery
Absolute values of cardiac function are presented in
Figure 6. Left ventricular work and cardiac output were sig-
nificantly lower for all ischemic groups compared to the
NWI group (St. T at 4˚C; p < 0.05 for all). No differences
were observed among ischemic groups. At 60 min reperfu-
sion, dP/dtmax was significantly decreased only in the
group with St. T at 4˚C compared with the non−ischemicgroup (p < 0.05). In general, dP/dtmin recovered less well
in all ischemic hearts compared with NWI hearts.Markers of cell death and mitochondrial damage
Release of cardiac troponin I (cTnI), heart-type fatty acid
binding protein (H-FABP) and cytochrome c (Cyt c) are
presented in Figure 7. For all markers, concentrations at
60 min reperfusion were significantly higher in all ischemic
groups compared with the NWI group (p < 0.05 for all).
Although levels of cell death markers tended to be lower in
the A-L at 22˚C group compared to other ischemic groups,
no statistically significant differences were observed among
ischemic groups.
Figure 4 Calcium content. (A) Calcium content in heart tissue; (B) Correlation between calcium content and left ventricular (LV) work
at 60 min reperfusion; (C) Correlation between calcium content and tissue CD138 (syndecan-1); (D) Correlation between calcium content
and Cyt c release. *p < 0.05 vs St. T 4˚C (NWI). Data are expressed as mean § SD and correlations data are expressed as Spearman’s rho
(r); n = 6 to 7 hearts per group. A-L, normokalemic adenosine-lidocaine solution; Cyt c, cytochrome c; NWI, no warm ischemia; St. T, St.
Thomas n˚2 solution.
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The following results are described in detail in the Support-
ing information section available online: coronary vascular
function (Figure S1), tissue water content (Figure S2),
mRNA expression of genes involved in inflammation after
60 min reperfusion (Figure S3), tissue protein expression of
inflammatory markers (Figure S4), oxygen consumption
and efficiency (Figure S5), representative protein carbonyl-
ation blot (Figure S6) and measurements during in-situ and/
or withdrawal phase in the series 1 of hearts (Table S3).
Discussion
Protective interventions at the onset of reperfusion are of
particular importance for minimization of I/R injury in
cardiac grafts obtained with DCD. In this study, we dem-
onstrate that tepid (22˚C) A-L preservation better pre-
serves cardiac grafts, particularly endothelial function,
compared to cold A-L or St. T, as demonstrated by
greater eNOS coupling (Figure 8). A significant reduc-
tion in oxidative stress was observed in hearts preserved
with tepid A-L, which could contribute to the increase in
eNOS dimers. Furthermore, tepid, A-L preservation bet-
ter preserves the endothelial glycocalyx, as indicated by
the retention of syndecan-1, whereas a significant losswas observed in hearts preserved with cold St. T vs NWI
hearts. As expected, tissue calcium content tended to be
higher in hearts preserved with St. T compared with A-L
at 22˚C, as St. T is hyperkalemic. Although both St. T
and A-L solutions included supplements to activate the
RISK pathway, stimulation appeared more effective with
tepid A-L than cold St. T, as demonstrated by increased
phosphorylation of Akt. Taken together, reduced calcium
content, and oxidative stress, in combination with the
increased recruitment of the cardioprotective RISK path-
way, likely contribute to improved graft preservation
provided with tepid, A-L preservation.
Coronary flow during loaded reperfusion was signifi-
cantly lower in ischemic hearts preserved with St. T at 4˚C
compared to the NWI group, while that of hearts with A-L
was not different compared to the NWI group. Although
hypothermia after a period of warm global ischemia has
been shown to increase endothelial injury,13,14,24 it is
unlikely to be entirely responsible for reduced coronary
flow, as coronary flow in the 4˚C A-L group was not signifi-
cantly different than NWI and almost identical to that in
hearts with tepid A-L. Rather, high potassium content in
hearts preserved with St. T after exposure to a period of
warm ischemia in combination with glycocalyx shedding
(as described below) may result in impaired endothelial
function.14
Figure 5 Activation of key signaling molecules. (A) Representative western blots for phosphorylated (Ser 1177) and total eNOS pro-
teins; (B) Ratios of phosphorylated (Ser 1177) to total proteins for eNOS, (C) Representative western blots for phosphorylated (Ser 473)
and total Akt proteins (D) Ratios of phosphorylated (Ser 473) to total proteins for Akt, *p < 0.05 vs St. T. 4˚C (NWI), ˚p < 0.05, Kruskal
Wallis analysis reported no significant differences for Panel A (p-value: 0.22). Data are expressed as mean § SD; n = 6 to 8 per group. A-L,
normokalemic adenosine-lidocaine solution; kDa, kilodalton; NWI, no warm ischemia; St. T, St. Thomas n˚2 solution.
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dimerization compared to cold A-L or St. T in our DCD
model in parallel with less oxidative stress, indicating better
eNOS coupling, and endothelial integrity. Consequently,
reduced coronary flow during reperfusion in ischemicFigure 6 Post-ischemic cardiac function. (A) LV work (left ventricu
(C) dP/dtmax (maximum first derivative of LV pressure); (D) dP/dtmin
(NWI). Data are expressed as mean § SD; n = 6 to 8 per group. A-L, nor
St. T, St. Thomas n˚2 solution.hearts with St. T likely stems from lower nitric oxide (NO)
production as a result of reduced dimer preservation. Under
physiologic conditions, NO is mainly produced by eNOS,
which converts L-arginine into NO and L-citrulline in the
presence of oxygen, calmodulin, tetrahydrobiopterin (BH4),lar work: heart rate*developed pressure); (B) CO (cardiac output);
(minimum first derivative of LV pressure). *p < 0.05 vs St. T 4˚C
mokalemic adenosine-lidocaine solution; NWI, no warm ischemia;
Figure 7 Release of markers of cell death and mitochondrial damage at 60 min reperfusion. (A) Release of cardiac troponin I (cTnI); (B)
Release of heart-type fatty acid binding protein (H-FABP) and (C) Release of cytochrome c (Cyt c). *p < 0.05 vs St. T 4˚C (NWI). Data are
expressed as mean § SD; n = 6 to 8 per group. A-L, normokalemic adenosine-lidocaine solution; NWI, no warm ischemia; St. T, St.
Thomas n˚2 solution.
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NADPH.25 One of the main causes of impaired endothelial
function after I/R is the lack of availability of NO.26,27 I/R
induces depletion of BH4 levels as a result of its oxidation
and/or reduced synthesis, which provokes eNOS uncou-
pling.28 When eNOS is uncoupled, the disturbed electron
flux leads to the production of superoxide (O2) instead of
NO.28 In turn, O2 can react with NO producing peroxyni-
trite, thereby creating a vicious cycle of exacerbated
eNOS uncoupling through further BH4 oxidation and
dimer destabilization.29 eNOS dimerization is required for
NO production. Thus, given their greater dimer content,
hearts with tepid A-L should have greater NO production
and reduced superoxide and peroxynitrite production com-
pared with the other ischemic hearts. This is in agreement
with our findings for lower oxidative stress in hearts pre-
served with A-L at 22˚C compared with other ischemic
hearts. Interestingly, for ischemic hearts preserved with
A-L, eNOS coupling was significantly greater at 22˚C
compared to 4˚C. The reason for this difference is not
immediately apparent. Although all hearts with A-L
received reduced glutathione and mannitol30 to limit reac-
tive oxygen species (ROS) production and promote eNOS
coupling, it appears that this approach is more effective at
warmer temperatures as demonstrated by our protein car-
bonylation results. Interestingly, although we couldobserve greater eNOS dimer preservation in hearts sub-
jected to A-L at 22˚C, no differences in eNOS phosphory-
lation were observed among groups. This pattern was
observed as well by Bibli et al. when they examined the
effects of GTN on eNOS.31
In addition, ischemic hearts preserved with St. T at 4˚C
suffered from glycocalyx shedding which could contribute
to the reduction in coronary flow. Our marker for cardiac
glycocalyx levels, syndecan-1, remained similar in NWI
hearts and hearts with A-L, but was significantly reduced
with St. T at 4˚C. The glycocalyx plays an important role in
preserving endothelial cell integrity and is required for
proper eNOS function.32 Furthermore, it is one of the first
structures to sustain damage as consequence of I/R.33,34
Indeed, I/R promotes glycocalyx disruption, leading to
edema, increased coronary perfusion pressure, and impaired
endothelial-dependent vasodilation.35,36
Ischemic hearts preserved with St. T at 4˚C tended to
have a higher tissue calcium content compared with hearts
preserved with A-L. In fact, calcium content correlated pos-
itively with cardiac dysfunction and mitochondrial damage,
which could be expected, as hyperkalemic cardioplegia can
potentially exacerbate Ca2+ overload and increase reperfu-
sion injury.14 In addition, calcium content correlated posi-
tively with glycocalyx degradation, which is in agreement
with Jackson-Weaver et al.,37 who observed that I/R injury
Figure 8 Proposed effects of preservation conditions on coronary endothelium. (A) Current clinical preservation conditions (St. Thomas
n˚2 at 4˚C) following warm ischemia result in higher tissue calcium content, which promotes mitochondrial damage, leading to higher oxi-
dative stress compared with hearts not exposed to warm ischemia preserved under the same conditions (NWI). Although an increase in
eNOS dimers and RISK pathway activation could promote greater nitric oxide production in ischemic hearts compared to NWI, increased
levels of reactive oxygen species (as observed) will decrease NO availability by both reacting with available nitric oxide (NO) to produce
peroxynitrite and promoting NOS uncoupling. Reduced NO, together with decreased glycocalyx content, likely contributes to reduced coro-
nary flow upon normothermic reperfusion. (B) Compared to current clinical preservation conditions (St. Thomas n˚2 at 4˚C), preservation
with tepid adenosine-lidocaine (A-L at 22˚C) tends to reduce tissue calcium content, which likely contributes to the significantly reduced
oxidative stress. This lower oxidative stress, in combination with significant increases eNOS dimerization, promote greater NO production.
Increased NO, in parallel with better preservation of the endothelial glycocalyx likely contributes to improved coronary flow during normo-
thermic reperfusion. Furthermore, preservation with A-L solution increased pro-survival (RISK) signaling compared with St. T, which may
also contribute to superior cardiac graft preservation.
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glycocalyx damage in cultured cells.
Tepid A-L preservation leads to a greater activation of
prosurvival pathways compared with St. T. We measured a
significantly higher Akt phosphorylation in ischemic A-L
22˚C hearts compared with St T at 4˚C hearts, indicating a
stronger activation of the RISK pathway. Interestingly,
although both preservation solutions have components that
activate prosurvival kinases9,38-41; St. T was less effective
than A-L in our study. Another potential cardioprotective
pathway could be mediated by the cyclooxygenase 2
(COX-2). COX-2 can induce inflammation and
apoptosis42,43 in the human heart. However, recent studies
demonstrated that expression of COX-2 confers cardiopro-
tection in mouse hearts exposed to I/R.44,45 In our study, we
observed that COX-2 mRNA expression was induced in
hearts subjected to ischemia (Fig. S2, D) with a tendency
for higher levels in hearts subjected to A-L 22˚C. COX-2
mRNA levels in our study followed the same pattern as p-
Akt. Although it is not yet known if there is connection
between these 2 molecules in the heart, Akt regulates COX-
2 mRNA expression in cancer cells.46
The release of markers of cell death and mitochondrial
damage were significantly increased in all ischemic groups
compared to the non−ischemic group. We observed a ten-
dency for lower cTnI in the hearts preserved with A-L at
22˚C in comparison with A-L at 4˚C. This finding was in
agreement with those in a porcine model of DCD for which
lower endothelial and myocyte injury as well as lower cTnIrelease was reported in hearts preserved with A-L solution
at 25˚C compared to 5˚C.13 In addition, cytochrome c
tended to be higher in hearts preserved at 4˚C, which is in
agreement with other studies reporting a higher release of
damage-associated molecular patterns in endothelial cells
subjected to cold storage and warm reperfusion.47
We demonstrated a significantly greater NO-dependent
pre-vasodilation in ischemic hearts compared to NWI hearts
with the measured NOS-dependent CVR upon infusion of
the NOS inhibitor (L-NAME). Thus, caution is needed in
the interpretation of our vascular function results in
response to BK and SNP. This pre-dilation likely results
from vasodilators present in the preservation solutions.
Although both vasodilators GTN and adenosine are NO-
independent, they may also possess NO-dependent
characteristics.31,48 In contrast, although the NWI hearts
were also treated with St. T containing GTN, pre-vasodila-
tion response was significantly lower.
Although our findings indicate that the current clinical
approach in DCD heart transplantation may be improved by
optimization of the composition and conditions of applica-
tion of the preservation solution, additional research is
required to make evidence-based recommendations for
future protocol development. In the current study, we report
that use of tepid preservation solution was associated with
reduced oxidative stress and improved endothelial recovery
compared with cold preservation solution Recently, we
demonstrated that use of hypothermic, oxygenated perfu-
sion (HOPE) improved cardiac recovery compared to cold
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may be related to NO generation during HOPE due to the
presence of oxygen and the reduction of oxidative stress.
Given that protective interventions before ischemic onset
are limited for ethical reasons in DCD, and that much I/R
injury occurs in the first minutes of reperfusion, the precise
conditions and composition of the preservation solution
applied immediately after warm ischemia takes on great
importance. Ultimately, a balance combining the optimal
composition, temperature, and oxygen will likely be
required for optimal graft preservation.
This study has several limitations. The DCD model we
used does not take into account neurologic injury, which is
frequently present in DCD donors, and could potentially
lead to remote preconditioning. In our DCD model, WLST
was simulated through an asphyxiation by dissecting the rat
diaphragm, which could lead to a shorter period of time
between WLST, and circulatory arrest compared with
human DCD donors. In addition, in this rat model of DCD,
heparinization was required to prevent clot formation, and
consequently achieve an optimal reperfusion. However, in
some countries the use of antemortem heparin is not
allowed. Our hearts were reperfused using a crystalloid
buffer and not a blood-based perfusate as in the clinical sce-
nario and hearts were not transplanted. Lastly, although we
believe that St. T no. 2 may be detrimental to DCD hearts,
this has only been demonstrated with our findings at 4˚C,
further research would be required to confirm these results
at other temperatures.
In this study, we demonstrate that the use of tepid A-L
preservation improved eNOS coupling, glycocalyx preser-
vation, and activation of pro-survival pathways while
reducing oxidative stress compared with the hyperkalemic
preservation solution currently use in DCD protocols.
Applying cardioplegic solutions developed for DBD condi-
tions is unlikely to be ideal for graft preservation in DCD,
as hearts are subjected to warm ischemia, and arrested
before procurement. Understanding the physiologic status
of the heart at the time of procurement is critical for the
development of optimal cardioprotective therapies in DCD.
DCD grafts are submitted to a period of warm ischemia that
leads to depletion of energy stores (ATP), anaerobic metab-
olism causing intracellular acidosis,11,49 and reperfusion
may cause further damage through the rapid restoration of
the extracellular pH, calcium overload, ROS generation,
mitochondrial permeability transition pore opening and
activation of cell death pathways.50 In current, clinical
DCD protocols, hearts are generally reperfused and stored
briefly with cold, hyperkalemic cardioplegia (St. T). It is
known that hyperkalemic cardioplegia could exacerbate
Ca2+ overload and lead to increased reperfusion injury.14
Furthermore, in DCD conditions, cold cardioplegia has
been reported to provoke greater endothelial and myocyte
injury than tepid conditions.13 As such, room for improve-
ment exists with current clinical protocols in DCD heart
transplantation such that reperfusion injury could be limited
or even prevented. Careful selection of preservation condi-
tions, taking into consideration the physiologic changes
occurring during DCD and mechanisms of injuryupon reperfusion, should help optimize graft quality, and
permit the expansion of DCD heart transplantation in a safe
manner.Author contributions
NMC contributed to all aspects of this manuscript including
study planning and design, model development, performing
experiments, data collection and analysis, and preparation
of the manuscript. RW, MA, AS, NK, and AJ participated
in performing experiments, data collection and preparation
of the manuscript. TC participated in data analysis and
preparation of the manuscript. SL participated in study
planning and design, model development, data analysis,
and preparation of the manuscript. All authors contributed
to the article and approved the submitted version.Disclosure statement
The authors have no conflicts of interest to disclose. This
article and/or publication is based on work from COST
Action EU-CARDIOPROTECTION CA16225, supported
by the European Cooperation in Science and Technology.
This study was supported by a Project Grant from the Swiss
Heart Foundation (FF18089) and by the Stiftung zur
F€orderung der herzchirurgischen Forschung am Inselspital.
In addition, the authors thank Dr Daniel Rodriguez Gutier-
rez for the conceptual diagram illustration.Supplementary materials
Supplementary material associated with this article can be
found in the online version at https://doi.org/10.1016/j.hea
lun.2021.07.028.Supplementary data
Supplementary data associated with this article can be
found in the online version at www.jhltonline.org/.
References
1. Lund LH, Edwards LB, Dipchand AI, et al. The registry of the interna-
tional society for heart and lung transplantation: thirty-third adult heart
transplantation report—2016; focus theme: primary diagnostic indica-
tions for transplant. J Heart Lung Transplant 2016;35:1158-69. https://
doi.org/10.1016/j.healun.2016.08.017.
2. Longnus SL, Mathys V, Dornbierer M, Dick F, Carrel TP, Tevaearai
HT. Heart transplantation with donation after circulatory determina-
tion of death. Nat Rev Cardiol 2014;11:354-63. https://doi.org/
10.1038/nrcardio.2014.45.
3. Messer SJ, Axell RG, Colah S, et al. Functional assessment and trans-
plantation of the donor heart after circulatory death. J Heart Lung
Transplant 2016;35:1443-52. ht tps: / /doi .org/10.1016/j .
healun.2016.07.004.
4. Noterdaeme T, Detry O, Hans M-F, et al. What is the potential
increase in the heart graft pool by cardiac donation after circulatory
death?: potential of cardiac donation after circulatory death. Transpl
Int 2013;26:61-6. https://doi.org/10.1111/j.1432-2277.2012.01575.x.
5. Messer S, Cernic S, Page A, et al. A 5-year single-center early experi-
ence of heart transplantation from donation after circulatory-
ARTICLE IN PRESS
Mendez-Carmona et al. Effects of graft preservation conditions on coronary endothelium 11determined death donors. J Heart Lung Transplant 2020;39:1463-75.
https://doi.org/10.1016/j.healun.2020.10.001.
6. Chew HC, Iyer A, Connellan M, et al. Outcomes of donation after cir-
culatory death heart transplantation in Australia. J Am Coll Cardiol
2019;73:1447-59. https://doi.org/10.1016/j.jacc.2018.12.067.
7. Messer S, Page A, Axell R, et al. Outcome after heart transplantation
from donation after circulatory-determined death donors. J Heart
Lung Transplant 2017;36:1311-8. https://doi.org/10.1016/j.hea-
lun.2017.10.021.
8. Dhital KK, Iyer A, Connellan M, et al. Adult heart transplantation
with distant procurement and ex-vivo preservation of donor hearts
after circulatory death: a case series. The Lancet 2015;385:2585-91.
https://doi.org/10.1016/S0140-6736(15)60038-1.
9. White CW, Messer SJ, Large SR, et al. Transplantation of hearts
donated after circulatory death. Front Cardiovasc Med. 2018;5.
https://doi.org/10.3389/fcvm.2018.00008.
10. Messer S, Page A, Colah S, et al. Human heart transplantation from
donation after circulatory-determined death donors using normother-
mic regional perfusion and cold storage. J Heart Lung Transplant
2018;37:865-9. https://doi.org/10.1016/j.healun.2018.03.017.
11. White CW, Ali A, Hasanally D, et al. A cardioprotective preservation
strategy employing ex vivo heart perfusion facilitates successful trans-
plant of donor hearts after cardiocirculatory death. J Heart Lung
Transplant 2013;32:734-43. https://doi.org/10.1016/j.healun.2013.04.
016.
12. Messer S, Ardehali A, Tsui S. Normothermic donor heart perfu-
sion: current clinical experience and the future. Transpl Int Off J
Eur Soc Organ Transplant 2015;28:634-42. https://doi.org/10.
1111/tri.12361.
13. White CW, Ambrose E, M€uller A, et al. Avoidance of profound hypo-
thermia during initial reperfusion improves the functional recovery of
hearts donated after circulatory death: hypothermia inhibits DCD heart
resuscitation. Am J Transplant 2016;16:773-82. https://doi.org/
10.1111/ajt.13574.
14. Parolari A, Rubini P, Cannata A, et al. Endothelial damage during
myocardial preservation and storage. Ann Thorac Surg 2002;73:682-
90. https://doi.org/10.1016/S0003-4975(01)03029-6.
15. Heusch G. The coronary circulation as a target of cardioprotection.
Circ Res 2016;118:1643-58. https://doi.org/10.1161/CIRCRE-
SAHA.116.308640.
16. Bell RM, Yellon DM. Conditioning the whole heart—not just the car-
diomyocyte. J Mol Cell Cardiol 2012;53:24-32. https://doi.org/
10.1016/j.yjmcc.2012.04.001.
17. Lee JH, Okada K, Khush K, et al. Coronary endothelial dysfunction
and the index of microcirculatory resistance as a marker of subsequent
development of cardiac allograft vasculopathy. Circulation
2017;135:1093-5. https://doi.org/10.1161/CIRCULATIONAHA.116.
025268.
18. Mendez-Carmona N, Wyss RK, Arnold M, et al. Differential effects of
ischemia/reperfusion on endothelial function and contractility in dona-
tion after circulatory death. J Heart Lung Transplant 2019;38:767-77.
https://doi.org/10.1016/j.healun.2019.03.004.
19. Wyss RK, Mendez Carmona N, Arnold M, et al. Hypothermic, oxy-
genated perfusion (HOPE) provides cardioprotection via succinate
oxidation prior to normothermic perfusion in a rat model of donation
after circulatory death (DCD). Am J Transplant 2020: ajt.16258.
https://doi.org/10.1111/ajt.16258.
20. Arnold M, Mendez-Carmona N, Wyss RK, et al. Comparison of
experimental rat models in donation after circulatory death (DCD): in-
situ versus ex-situ Ischemia. Front Cardiovasc Med Sect Heart Fail
Transplant 2020. https://doi.org/10.3389/fcvm.2020.596883.
21. Dhital KK, Iyer A, Connellan M, et al. Adult heart transplantation
with distant procurement and ex-vivo preservation of donor hearts
after circulatory death: a case series. The Lancet 2015;385:2585-91.
https://doi.org/10.1016/S0140-6736(15)60038-1.
22. Bøtker HE, Hausenloy D, Andreadou I, et al. Practical guidelines for
rigor and reproducibility in preclinical and clinical studies on cardio-
protection. Basic Res Cardiol 2018;113:39. https://doi.org/10.1007/
s00395-018-0696-8.23. Holland BS, Copenhaver MD. An improved sequentially rejective
bonferroni test procedure. Biometrics 1987;43:417-23. https://doi.org/
10.2307/2531823.
24. Vinten-Johansen J, Nakanishi K. Postcardioplegia acute cardiac dys-
function and reperfusion injury. J Cardiothorac Vasc Anesth
1993;7:6-18. https://doi.org/10.1016/1053-0770(93)90092-Y.
25. Fleming I, Busse R. Molecular mechanisms involved in the regulation
of the endothelial nitric oxide synthase. 2003;284:12.
26. Tsao PS, Lefer AM. Time course and mechanism of endothelial dys-
function in isolated ischemic- and hypoxic-perfused rat hearts. Am J
Physiol-Heart Circ Physiol 1990;259:H1660-6. https://doi.org/
10.1152/ajpheart.1990.259.6.H1660.
27. Vinten-Johansen J, Zhao Z-Q, Nakamura M, et al. Nitric oxide and the
vascular endothelium in myocardial ischemia-reperfusion injurya.
Ann N Y Acad Sci 1999;874(1 HEART IN STRE):354-70. https://doi.
org/10.1111/j.1749-6632.1999.tb09251.x.
28. Otani H. The role of nitric oxide in myocardial repair and remodeling.
Antioxid Redox Signal 2009;11:1913-28. https://doi.org/10.1089/
ars.2009.2453.
29. Chen W, Druhan LJ, Chen C-A, et al. Peroxynitrite induces destruc-
tion of the tetrahydrobiopterin and heme in endothelial nitric oxide
synthase: transition from reversible to irreversible enzyme inhibition.
Biochemistry 2010;49:3129-37. https://doi.org/10.1021/bi9016632.
30. Maathuis M-HJ, Leuvenink HGD, Ploeg RJ. Perspectives in organ
preservation. Transplantation 2007;83:1289-98. https://doi.org/
10.1097/01.tp.0000265586.66475.cc.
31. Bibli S-I, Papapetropoulos A, Iliodromitis EK, et al. Nitroglycerine
limits infarct size through S-nitrosation of cyclophilin D: a novel
mechanism for an old drug. Cardiovasc Res 2019;115:625-36. https://
doi.org/10.1093/cvr/cvy222.
32. Zhang X, Sun D, Song JW, et al. Endothelial cell dysfunction and gly-
cocalyx − a vicious circle. Matrix Biol 2018;71-72:421-31. https://
doi.org/10.1016/j.matbio.2018.01.026.
33. Abassi Z, Armaly Z, Heyman SN. Glycocalyx degradation in ische-
mia-reperfusion injury. Am J Pathol 2020:S0002944020300729.
https://doi.org/10.1016/j.ajpath.2019.08.019.
34. Yu H, Kalogeris T, Korthuis RJ. Reactive species-induced microvas-
cular dysfunction in ischemia/reperfusion. Free Radic Biol Med
2019;135:182-97. https://doi.org/10.1016/j.freeradbiomed.2019.02.
031.
35. Chappell D, Jacob M, Hofmann-Kiefer K, et al. Antithrombin reduces
shedding of the endothelial glycocalyx following ischaemia/reperfu-
sion. Cardiovasc Res 2009;83:388-96. https://doi.org/10.1093/cvr/
cvp097.
36. Chappell D, Jacob M, Hofmann-Kiefer K, et al. Hydrocortisone pre-
serves the vascular barrier by protecting the endothelial glycocalyx.
Anesthesiology 2007;107:776-84. https://doi.org/10.1097/01.anes.
0000286984.39328.96.
37. Jackson-Weaver O, Friedman JK, Rodriguez LA, et al. Hypoxia/reox-
ygenation decreases endothelial glycocalyx via reactive oxygen spe-
cies and calcium signaling in a cellular model for shock. J Trauma
Acute Care Surg 2019;87:1070-6. https://doi.org/10.1097/
TA.0000000000002427.
38. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN,
Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin
receptor and nitric oxide production by endothelial cells. Blood
2004;104:2073-80. https://doi.org/10.1182/blood-2004-02-0744.
39. Burger D, Lei M, Geogheganmorphet N, Lu X, Xenocostas A, Feng Q.
Erythropoietin protects cardiomyocytes from apoptosis via up-regula-
tion of endothelial nitric oxide synthase. Cardiovasc Res 2006;72:51-
9. https://doi.org/10.1016/j.cardiores.2006.06.026.
40. Zhao Z-Q, Budde JM, Morris C, et al. Adenosine attenuates reperfu-
sion-induced apoptotic cell death by modulating expression of Bcl-2
and bax proteins. J Mol Cell Cardiol 2001;33:57-68. https://doi.org/
10.1006/jmcc.2000.1275.
41. Sato T, Sato H, Oguchi T, et al. Insulin preconditioning elevates p-Akt
and Cardiac contractility after reperfusion in the isolated ischemic rat
Heart. BioMed Res Int 2014;2014:1-6. https://doi.org/10.1155/2014/
536510.
ARTICLE IN PRESS
12 The Journal of Heart and Lung Transplantation, Vol 00, No 00, Month 202142. Abbate A. Cyclo-oxygenase-2 (COX-2) expression at the site of recent
myocardial infarction: friend or foe? Heart 2004;90:440-3. https://doi.
org/10.1136/hrt.2003.010280.
43. Chenevard R, H€urlimann D, Bechir M, et al. Selective COX-2 inhibi-
tion improves endothelial function in coronary artery disease. Circula-
tion 2003;107:405-9. https://doi.org/10.1161/01.CIR.0000051361.
69808.3A.
44. Inserte J, Molla B, Aguilar R, et al. Constitutive COX-2 activity
in cardiomyocytes confers permanent cardioprotection. J Mol Cell
Cardiol 2009;46:160-8. https://doi.org/10.1016/j.yjmcc.2008.11.
011.
45. Guo Y, Nong Y, Tukaye DN, et al. Inducible cardiac-specific overex-
pression of cyclooxygenase-2 (COX-2) confers resistance to ischemia/
reperfusion injury. Basic Res Cardiol 2019;114:32. https://doi.org/
10.1007/s00395-019-0741-2.46. St-Germain M-E, Gagnon V, Mathieu I, Parent S, Asselin E. Akt regu-
lates COX-2 niRNA and protein expression in mutated-PTEN human
endometrial cancer cells. Int J Oncol 2004:14.
47. Tran DT, Esckilsen S, Mulligan J, Mehrotra S, Atkinson C, Nadig SN.
Impact of mitochondrial permeability on endothelial cell immunoge-
nicity in transplantation. 2018;102:10.
48. Silva L, Subiabre M, Araos J, et al. Insulin/adenosine axis linked sig-
nalling. Mol Aspects Med 2017;55:45-61. https://doi.org/10.1016/j.
mam.2016.11.002.
49. Ali AA, White P, Xiang B, et al. Hearts from DCD donors display
acceptable biventricular function after heart transplantation in pigs:
heart transplantation from DCD donors. Am J Transplant
2011;11:1621-32. https://doi.org/10.1111/j.1600-6143.2011.03622.x.
50. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J
Med 2007: 15.
